ACLARIS THERAPEUTICS INC's ticker is ACRS and the CUSIP is 00461U105. A total of 117 filers reported holding ACLARIS THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 1.10 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $38,414,046 | -33.8% | 5,607,890 | +0.2% | 0.00% | -50.0% |
| Q2 2023 | $58,011,574 | +40.2% | 5,594,173 | +9.4% | 0.00% | +100.0% |
| Q1 2023 | $41,383,369 | -48.4% | 5,115,373 | +0.5% | 0.00% | -66.7% |
| Q4 2022 | $80,146,383 | +5.9% | 5,088,659 | +5.8% | 0.00% | 0.0% |
| Q3 2022 | $75,714,000 | +16.1% | 4,810,298 | +3.0% | 0.00% | +50.0% |
| Q2 2022 | $65,191,000 | -5.2% | 4,669,916 | +17.1% | 0.00% | 0.0% |
| Q1 2022 | $68,738,000 | +15.9% | 3,987,107 | -2.2% | 0.00% | 0.0% |
| Q4 2021 | $59,307,000 | -13.0% | 4,078,875 | +7.7% | 0.00% | 0.0% |
| Q3 2021 | $68,192,000 | +19.9% | 3,788,417 | +17.0% | 0.00% | 0.0% |
| Q2 2021 | $56,878,000 | +129.2% | 3,239,049 | +228.9% | 0.00% | +100.0% |
| Q1 2021 | $24,819,000 | +294.1% | 984,876 | +1.2% | 0.00% | – |
| Q4 2020 | $6,297,000 | +135.5% | 973,170 | -6.5% | 0.00% | – |
| Q3 2020 | $2,674,000 | +57.6% | 1,040,370 | -0.7% | 0.00% | – |
| Q2 2020 | $1,697,000 | -37.9% | 1,047,816 | -60.1% | 0.00% | – |
| Q1 2020 | $2,732,000 | -45.2% | 2,626,521 | -0.5% | 0.00% | – |
| Q4 2019 | $4,988,000 | +52.3% | 2,639,569 | -12.9% | 0.00% | – |
| Q3 2019 | $3,275,000 | -49.9% | 3,031,769 | +1.6% | 0.00% | – |
| Q2 2019 | $6,534,000 | -65.2% | 2,983,109 | -4.8% | 0.00% | -100.0% |
| Q1 2019 | $18,765,000 | -29.9% | 3,132,933 | -13.5% | 0.00% | 0.0% |
| Q4 2018 | $26,759,000 | -26.8% | 3,620,835 | +43.8% | 0.00% | -50.0% |
| Q3 2018 | $36,551,000 | -20.8% | 2,517,412 | +8.9% | 0.00% | 0.0% |
| Q2 2018 | $46,163,000 | +25.0% | 2,311,641 | +9.7% | 0.00% | 0.0% |
| Q1 2018 | $36,921,000 | -31.8% | 2,107,426 | -4.0% | 0.00% | -33.3% |
| Q4 2017 | $54,129,000 | +22.7% | 2,195,028 | +28.4% | 0.00% | +50.0% |
| Q3 2017 | $44,132,000 | +35.7% | 1,709,882 | +42.5% | 0.00% | 0.0% |
| Q2 2017 | $32,531,000 | +39.7% | 1,199,526 | +53.6% | 0.00% | +100.0% |
| Q1 2017 | $23,291,000 | +122484.2% | 781,043 | +111477.6% | 0.00% | – |
| Q4 2016 | $19,000 | +46.2% | 700 | +40.0% | 0.00% | – |
| Q3 2016 | $13,000 | -18.8% | 500 | -41.1% | 0.00% | – |
| Q2 2016 | $16,000 | +128.6% | 849 | +143.3% | 0.00% | – |
| Q1 2016 | $7,000 | – | 349 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management V, LLC | 1,258,243 | $8,618,965 | 13.75% |
| Foresite Capital Management IV, LLC | 2,808,034 | $19,235,033 | 10.68% |
| Bain Capital Life Sciences Investors, LLC | 3,400,000 | $23,290,000 | 2.60% |
| GREAT POINT PARTNERS LLC | 1,691,768 | $11,588,611 | 2.11% |
| Samsara BioCapital, LLC | 696,171 | $4,768,771 | 1.46% |
| Altium Capital Management LP | 403,000 | $2,760,550 | 1.44% |
| BVF INC/IL | 7,064,736 | $48,393,442 | 1.30% |
| Aisling Capital Management LP | 434,455 | $2,976,017 | 1.23% |
| GREAT POINT PARTNERS LLC | 700,000 | $4,795,000 | 0.87% |
| VR Adviser, LLC | 1,040,754 | $7,129,165 | 0.75% |